TrialJournal for immunotherapy of cancer2025

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).

Giovanni Grignani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.